Citation Impact
Citing Papers
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
2008
Functionally specialized junctions between endothelial cells of lymphatic vessels
2007 Standout
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Regulation of Type II Transmembrane Serine Proteinase TMPRSS6 by Hypoxia-inducible Factors
2010 StandoutNobel
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy
2007
Guidelines for a genetic risk based approach to advising women with a family history of breast cancer
2000
Axillary recurrence in breast cancer
2005
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
1999 Standout
Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity
2000 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
2009 StandoutNobel
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
2004
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
1997
Cellular senescence in aging and age-related disease: from mechanisms to therapy
2015 Standout
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
2009 Standout
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
2006 Standout
The biology and function of fibroblasts in cancer
2016 Standout
In vitro and in vivo biologic evaluation of long‐circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668
2003
Sulfation of bisphenol A abolished its estrogenicity based on proliferation and gene expression in human breast cancer MCF-7 cells
2002
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
2013
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
Genetic upregulation of matriptase‐2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation
2008
Clinical potential of new antiestrogens.
1997
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Monitoring of hormonal drug effect in a single breast cancer cell using an estrogen responsive GFP reporter vector delivered by a nanoneedle
2008
Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer
2007
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer
1988
Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines
1995
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
2004
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2005 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
1998 Standout
Lymphatic endothelium‐specific hyaluronan receptor LYVE‐1 is expressed by stabilin‐1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis
2006
PROTAC targeted protein degraders: the past is prologue
2022 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification
2007
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis
2013 Standout
European studies on breast lymphatic mapping
2004
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
2004 Standout
Microneedles for drug and vaccine delivery
2012 Standout
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
2004
Identifying suspected breast cancer: development and validation of a clinical prediction rule
2011
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
2004
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
2011 StandoutNature
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
1998 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
Differential Control of Transcription by DNA-bound Cyclins
2001 StandoutNobel
Fluorine in medicinal chemistry
2007 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity
2013
Estrogen Receptors as Therapeutic Targets in Breast Cancer
2008
How To Build and Interpret a Nomogram for Cancer Prognosis
2008 Standout
Preliminary experience with pure antiestrogens.
2001
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Aging, Cellular Senescence, and Cancer
2012 Standout
The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
2010 Standout
The Lymphatic System: Integral Roles in Immunity
2016 Standout
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
2005 Standout
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
The coregulator exchange in transcriptional functions of nuclear receptors
2000 Standout
Basic Guide to the Mechanisms of Antiestrogen Action
1998
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells
2003
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
2015
Cancer incidence and risk factors after solid organ transplantation
2009
The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer
1992
Mechanisms of Estrogen Action
2001 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Four faces of cellular senescence
2011 Standout
Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L‐type Ca 2+ channels in smooth muscle cells
1998
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Bisphenol-A and the Great Divide: A Review of Controversies in the Field of Endocrine Disruption
2009 Standout
Reshaping de Novo Protein Switches into Bioresponsive Materials for Biomarker, Toxin, and Viral Detection
2022 StandoutNobel
Senescent Human Fibroblasts Increase the Early Growth of Xenograft Tumors via Matrix Metalloproteinase Secretion
2007
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Breast Ductal Secretions: Clinical Features, Potential Uses, and Possible Applications
2007
The complexus adhaerens of mammalian lymphatic endothelia revisited: a junction even more complex than hitherto thought
2005
Works of R.E. Mansel being referenced
The National Breast Referral Guidelines have cut down inappropriate referrals in the under 50s
1999
ABC of Breast Diseases : Symptoms Assessment and Guidelines for Referral
1994
Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist
2003
ONCOPOOL – A European database for 16,944 cases of breast cancer
2009
Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer
1992
Evaluation of general practitioner referrals to a specialist breast clinic according to the UK national guidelines
1997
The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision)
1998
Axillary dissection in breast cancer
1991
Current status of the EORTC 10981–22023 AMAROS trial – After mapping of the axilla radiotherapy or surgery
2008
Tamoxifen as sole therapy for localised breast cancer
1986
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
1994
Cyclosporin A and multiple fibroadenomas of the breast
1996
Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial
2004
Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens.
1997
Lymphangiogenesis and its role in cancer.
2005